Latigo, BlossomHill launch US IPOs as biotech listings rebound

• Latigo Biotherapeutics is developing non-opioid pain medicines, with lead candidate LTG-001 targeting moderate to severe acute pain including postoperative pain, with Goldman Sachs and Jefferies as underwriters
• BlossomHill Therapeutics, founded in 2020, focuses on small molecule drug discovery for oncology and autoimmune disorders, offering 7.8 million shares with J.P. Morgan and Leerink Partners leading
• Continued geopolitical tensions in the Middle East could stall the biotech IPO rally by fueling inflation and keeping interest rates elevated, raising costs for cash-intensive drug developers

Summary: Biotech IPOs Rebound with Latigo and BlossomHill Launches

Two drug development companies launched U.S. IPOs on Monday, August 3, signaling a rebound in biotech listings amid renewed capital flows.

Latigo Biotherapeutics (Thousand Oaks, CA):

• Targeting $1.08 billion valuation
• Seeking to raise $288 million through 16 million shares
• Focuses on developing non-opioid pain medications to address addiction risks
• Lead candidate LTG-001: oral inhibitor for moderate to severe acute pain, including postoperative pain
• Underwriters: Goldman Sachs, Jefferies, Leerink Partners, Guggenheim Securities

BlossomHill Therapeutics (San Diego, CA):

• Targeting $494.38 million valuation
• Seeking to raise $132.8 million through 7.8 million shares
• Founded in 2020 as small molecule drug discovery company
• Focus areas: oncology and autoimmune disorders
• Underwriters: J.P. Morgan, Leerink Partners, Guggenheim Securities, LifeSci Capital, H.C. Wainwright & Co.

Market Implications:

The biotech IPO resurgence reflects improved investor appetite for healthcare offerings. However, analysts warn the rally faces potential headwinds from Middle East tensions that could drive inflation higher, keeping interest rates elevated for longer periods. This scenario would increase funding costs for capital-intensive drug developers, potentially dampening the sector's momentum.

The combined $420.8 million in targeted proceeds from both offerings demonstrates significant institutional confidence in biotech innovation, particularly in pain management and oncology therapeutics, though macro-economic uncertainties remain a key risk factor for sustained sector growth.